Precigen Shares Soar 40% on FDA Approval of PAPZIMEOS™
By ATTN Desk · Editorial oversight: Sean Han
Introduction to Precigen, Inc.
Precigen, Inc. (NASDAQ: PGEN) is an American biotechnology company headquartered in Germantown, Maryland. The company specializes in gene and cell therapy technologies aimed at developing precision medicines for immuno-oncology, autoimmune disorders, infectious diseases, and rare conditions.
Corporate Structure
Precigen employs between 51 and 200 staff, including scientists, clinicians, researchers, and business professionals. The leadership team is led by President and CEO Helen Sabzevari, PhD. The company emphasizes an inclusive culture that draws on diverse expertise across research, clinical development, and regulatory affairs.
Gene therapy by Sangharsh Lohakare
Recent Developments
On August 15, 2025, Precigen shares closed at $2.59, reflecting a 40.00% increase with a trading volume of 16,409,279 shares on the NASDAQ exchange. Precigen's website reported that the U.S. Food and Drug Administration approved PAPZIMEOS™ (zopapogene imadenovec-drba) for subcutaneous injection (5×10¹¹ PU/mL), marking the company's first U.S. commercial product.
Financial and Strategic Analysis
Precigen's market capitalization was approximately $551 million as of August 15, 2025. For the trailing twelve months ended June 30, 2025, the company reported $4.34 million in revenue and a net loss of $124.5 million. Key financial metrics as of August 15, 2025:
| Metric | Value |
|---|---|
| Stock Price (2025-08-15) | $2.59 |
| Market Cap (intraday) | $551.25 million |
| Enterprise Value | $476.42 million |
| Revenue (TTM) | $4.34 million |
| Net Income (TTM) | –$124.5 million |
| Price/Sales (TTM) | 122.82 |
| Return on Assets (TTM) | –67.44% |
| Return on Equity (TTM) | –668.03% |
| Total Cash (MRQ) | $59.75 million |
| Trading Volume (2025-08-15) | 16,409,279 shares |
Precigen's cash position supports ongoing research and development, as well as the commercial launch of PAPZIMEOS™. The enterprise value to revenue ratio reflects investor expectations regarding the company's developmental progress.
Market Position and Industry Context
Operating within the gene and cell therapy sector, Precigen utilizes its proprietary AdenoVerse® and UltraCAR-T® platforms to develop therapies. The FDA approval of PAPZIMEOS™ for recurrent respiratory papillomatosis establishes a commercial presence in a rare disease market. The industry comprises multiple companies developing therapies for oncology and rare diseases, with Precigen's focus on precision medicines aligning with the overall shift toward targeted, biologically based treatments.
TL;DR
On August 15, 2025, Precigen's shares increased 40.00% to $2.59 following FDA approval of PAPZIMEOS™. With $59.75 million in cash and its first U.S. commercial product, the company is positioned to advance its AdenoVerse® and UltraCAR-T® pipeline through 2026.